L3VLUP
ProSign in

GILD · ARGX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

GILDARGX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • GILD
  • ARGX
010203040202120222023202420252026
Holders and value by quarter
QuarterGILDARGX
Q3 202025 holders, $14.2bn8 holders, $3.6bn
Q4 202027 holders, $13.4bn7 holders, $4.1bn
Q1 202124 holders, $14.5bn8 holders, $4.1bn
Q2 202118 holders, $14.9bn9 holders, $4.6bn
Q3 202120 holders, $16.4bn8 holders, $4.5bn
Q4 202120 holders, $16.8bn9 holders, $5.3bn
Q1 202228 holders, $13.2bn8 holders, $5.3bn
Q2 202226 holders, $13.6bn13 holders, $6.5bn
Q3 202224 holders, $13.3bn14 holders, $5.3bn
Q4 202232 holders, $21.1bn13 holders, $5.5bn
Q1 202327 holders, $21.8bn13 holders, $5.9bn
Q2 202324 holders, $20.7bn18 holders, $6.6bn
Q3 202324 holders, $20.0bn21 holders, $8.7bn
Q4 202322 holders, $21.5bn17 holders, $6.3bn
Q1 202430 holders, $20.3bn13 holders, $6.8bn
Q2 202428 holders, $18.5bn14 holders, $7.9bn
Q3 202429 holders, $24.2bn13 holders, $10.7bn
Q4 202428 holders, $25.9bn14 holders, $12.3bn
Q1 202533 holders, $32.0bn17 holders, $11.8bn
Q2 202527 holders, $30.9bn18 holders, $10.8bn
Q3 202523 holders, $29.4bn16 holders, $13.8bn
Q4 202525 holders, $34.3bn16 holders, $14.8bn
Q1 202625 holders, $38.5bn11 holders, $12.3bn
Q2 202626 holders, $34.2bn14 holders, $15.0bn
GILD

Gilead Sciences Inc

Holders
30
Reported value
$20.3bn
Buyers
17
Sellers
12

Breadth +5 among 93 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
ARGX

Argenx Se

Holders
13
Reported value
$6.8bn
Buyers
6
Sellers
8

Breadth -2 among 93 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q1 2024

Among the 37 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only GILD (24)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Eisler Capital Management Ltd, Invesco Ltd, Man Group PLC, Neuberger Berman Group LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, Tudor Investment Corp, Two Sigma Advisers LP, Two Sigma Investments LP, Voloridge Investment Management LLC, Wellington Management Group LLP, Winton Group Ltd, Woodline Partners LP

Only ARGX (7)

Artisan Partners LP, ExodusPoint Capital Management LP, Holocene Advisors LP, Marshall Wace LLP, MFS Investment Management, Moore Capital Management LP, Soros Fund Management LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →